



atbtherapeutics raises additional €3.9M seed financing to further advance a novel class of therapeutic agent for oncology

Belgium, 23 December 2019 – atbtherapeutics, a pioneering biopharmaceutical company building a pipeline of novel biologic agents for hard-to-treat and refractory cancer using its antibody–toxin-bioengineered **atbody** format, announces the closing of an additional seed financing round, raising €3.9M.

The proceeds will support the Company in discovery developments of two programs in haematological malignancies and solid tumours, targeting *in vivo* proof of concept. The funds will also be used to expand in-house product design, preclinical and process development capabilities, secure manufacturing towards the clinic, and strengthen the team with new hires.

The seed extension was co-led by existing investors Financière spin-off, Luxembourgeoise, and Fondation Fournier-Majoie. Luxembourg Development complemented the historic syndicate and additional support was granted by the Region Wallonne.

atbtherapeutics is developing its **atbody** format, a novel class of biologic that offers a new line of attack against haematological malignancies and solid tumours. The development of this novel class of biologic agent is driven by the Company's unique **atbiofarm** single-step manufacturing technology.

Bertrand Magy, atbtherapeutics' CEO, said:

"We have made great progress in the past couple of years, having shown the feasibility of **atbodies** within plant systems, and filed patents for our disruptive **atbiofarm** manufacturing technology. This additional seed financing will allow us to make critical steps forward, including two discovery programs.

"I'd like to thank our investors for their continued support."

Jérôme Majoie, CEO of Fondation Fournier-Majoie, added:

"**atbtherapeutics** is an exciting young company with a promising technology that could prove to be highly influential in cancer therapy in the future. We're pleased to continue our support for the Company and will follow its progress with great interest."

ENDS

For more information please contact

atbtherapeutics
Dr Bertrand Magy, CEO
Email: bertrand.magy@atbtherapeutics.com

Instinctif Partners

Dr Christelle Kerouedan / Siobhan Sanford
Tel: +44 (0)20 7457 2020
Email: atbtherapeutics@instinctif.com

Notes to Editors

About **atb**therapeutics

atbtherapeutics is a pioneering biopharmaceutical company committed to building a pipeline of novel biologic agents for hard-to-treat and refractory cancer.

atbtherapeutics advance the development of its antibody-toxin-bioengineered -“**atbody**”: a game-changer format of antibody-based therapy. The **atbody** is a new line of attack dedicated to broaden the therapeutic window of targeted therapies. Its unique composition, avoiding chemical linker issues, has the potential to increase potency, stability and targeted exposure. The differentiated mechanism of action is meant to allow to evade major mechanisms of cancer cell resistance, providing a promising life-changing therapy for cancer.

The **atbody** is enabled by our versatile plant based **atbiofarm** technology. The **atbiofarm** technology leverages plant expression systems in a truly distinct method of production, in a single step manufacturing, avoiding chemical conjugation issues

atbtherapeutics is a private company headquartered in Belgium. It was founded in 2018 with seed financing from Financière Spin Off Luxembourgeoise, the Fournier-Majoie Foundation, and Noshaq. It has raised a total of EUR 5 million in equity and subsidies with additional investment from historical investors and Luxembourg Development.